TELA Bio's Q1 Revenue Growth Misses Full-Year Target, Net Loss Widens
Summary
TELA Bio reported first-quarter 2026 financial results, with revenue of $19.1 million, representing a modest 3% year-over-year increase, and a widened net loss of $12.3 million compared to $11.3 million in the prior year period. Despite the soft Q1 performance, the company reiterated its full-year 2026 revenue guidance of at least 8% growth over 2025 and projected Q2 revenue of approximately $20.0 million. This significant gap between Q1 growth and full-year guidance, coupled with the increasing net loss, raises concerns about the company's ability to accelerate growth and manage profitability, especially for a small-cap company that recently received a Nasdaq delisting notice as per its 10-K. Traders will be closely watching for signs of the anticipated ramp-up in subsequent quarters to meet the reiterated guidance.
At the time of this announcement, TELA was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.6M. The 52-week trading range was $0.50 to $2.20. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.